
Endocrinology
Latest News
Latest Videos
More News


The algorithm adds a new diabetes classification pathway and expands comorbidity-driven pharmacotherapy guidance, incorporating recent trial data on GLP-1 receptor agonists, SGLT2 inhibitors, and MASLD.

Once-weekly insulin makes injections simpler, boosts adherence, and lets clinics train patients fast—ideal for older adults.

Which patients are most likely to benefit from once-weekly insulin? Early insights on insulin icodec for adults with type 2 diabetes, here.

The FDA has approved Awiqli® (insulin icodec-abae), the first once-weekly basal insulin for adults with type 2 diabetes, reducing injections from 7 to 1 per week.

Replacing 30 minutes of sedentary time with sleep or exercise was linked to lower insulin resistance in teens in preliminary AHA EPI 2026 data.

FDA clears MiniMed Flex insulin pump with smartphone control and adaptive algorithm for type 1 and insulin-requiring type 2 diabetes.

ATTD 2026: Registry data from US primary care practices showed Dexcom G7 use lowered HbA1c by 0.7% over 1 year in adults with noninsulin-treated type 2 diabetes.

The FDA issued 30 warning letters to telehealth firms for false or misleading claims about compounded GLP-1 products, citing illegal marketing practices.

GLP‑1 therapy reduces asthma flare-ups in overweight non‑diabetics, suggesting a promising add-on for obesity-related asthma care.

FDA approves DESMODA, a ready-to-use desmopressin acetate oral solution, enabling precise titration for central diabetes insipidus with key hyponatremia warnings.

Obesity medicine specialist Monu Khanna, MD, discusses the critical role of primary care in obesity-related risk reduction through lifestyle, behavior, and emerging therapies.

The FDA updates Afrezza's prescribing information, enhancing dosing guidance for adults switching from injected insulin to improve glycemic control.

FDA requests removal of suicidal ideation warnings from GLP-1 receptor agonist labeling after a comprehensive review found no increased risk.

Weight-loss interventions significantly enhance psoriasis severity and quality of life, emphasizing their role in effective psoriasis management strategies.

A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

A nephrology expert discusses survey findings that reveal gaps between UACR testing and action in cardiovascular risk assessment for type 2 diabetes.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

CGM users experienced fewer ED and inpatient days and better glycemic outcomes, but most eligible adults in this large cohort did not use the technology.

Ob/gyn Dorr outlines how short clinical visits and symptom overlap cause many women to receive an antidepressant Rx instead of perimenopause care.

The 2026 annual updates to the Standards of Care in Diabetes include wider CGM use, guidance on dosing of antiobesity drugs, and glycemic management during cancer therapy.

Insulet enhances the Omnipod® 5 system with new glucose targets and algorithms, improving insulin delivery for diabetes management.

Semaglutide did not slow AD progression in phase 3 evoke trials. UK and US experts express disappointment but laud value of outcomes to continuing research.
























































































































































